• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Intra-Cellular Ther (NQ: ITCI )

    86.54 +1.79 (+2.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Intra-Cellular Ther

    < Previous 1 2 3 4 5 Next >
    Earnings Preview For Intra-Cellular Therapies
    Via Benzinga
    Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)
    Via Benzinga
    Expert Ratings For Intra-Cellular Therapies
    Via Benzinga
    This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
    Via Benzinga
    Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
    Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. 
    Via Investor's Business Daily
    Topics Earnings
    Exposures Financial
    Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings)
    Via Benzinga
    NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
    Via Benzinga
    Where Intra-Cellular Therapies Stands With Analysts
    Via Benzinga
    China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
    Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). 
    Via Benzinga
    Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
    Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
    Via Investor's Business Daily
    Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
    Intra-Cellular Therapies reports positive topline results for Study 502 on lumateperone 42 mg as adjunctive therapy for major depressive disorder. FDA application expected in H2 2024. 
    Via Benzinga
    Exposures Product Safety
    Analyst Ratings For Intra-Cellular Therapies
    Via Benzinga
    The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
    Via Benzinga
    How Is The Market Feeling About Intra-Cellular Therapies?
    Via Benzinga
    Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win
    The company hopes to expand its antipsychotic drug to depression treatment. 
    Via Investor's Business Daily
    The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio
    While it’s comforting to pick the ideas of the masses, these overlooked stocks may offer superior upside potential for the daring. 
    Via InvestorPlace
    ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024
    ITCI stock results show that Intra-Cellular Therapies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    3 Biotech Stocks With Skyrocketing Potential: April 2024
    These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. 
    Via InvestorPlace
    Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
    The Nasdaq and S&P 500 tumbled below their 50-day lines. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
    Via Benzinga
    Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
    With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
    Via Benzinga
    Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
    Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants. 
    Via Benzinga
    UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results
    Intra-Cellular Therapies is trying to position its antipsychotic in depression treatment. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.